Table 3.
Anti‐HLA antibodies
| Variable | eDSA+/IgGAM+ (n = 128) | eDSA− (n = 452) | P value |
|---|---|---|---|
| Preoperative anti‐HLA antibodies | |||
| Anti‐HLA I | 26 (20) | 83 (18) | .62 |
| Anti‐HLA II | 40 (31) | 86 (19) | .003 |
| Anti‐HLA I + anti‐HLA II | 9 (7) | 24 (5) | .46 |
| Cumulative mismatches | |||
| HLA A + B | 3 (2‐4) | 3 (3‐4) | .04 |
| HLA A + B + DR | 5 (4‐6) | 5 (4‐5) | <.001 |
| Postoperative anti‐HLA antibodiesa | |||
| Anti‐HLA I | 56 (44) | 98 (22) | <.001 |
| Anti‐HLA II | 111 (87) | 116 (26) | <.001 |
| Anti‐HLA I + anti‐HLA II | 43 (34) | 45 (10) | <.001 |
| Postoperative anti‐HLA eDSA | |||
| HLA A | 15 (12) | ||
| HLA B | 21 (16) | ||
| HLA C | 2 (2) | ||
| HLA DR | 12 (9) | ||
| HLADQ | 103 (81) | ||
| Positive crossmatch | 10 (8) | ||
Values are expressed as median (IQR) or N of patients (%). eDSA, early donor specific antibodies; HLA, human leukocyte antigen; IgGAM, IgA‐ and IgM‐enriched intravenous human immunoglobulins.All patients who developed anti‐HLA antibodies after lung transplantation were considered, independently of DSA positivity.